arrow
L

Laura Mannarino

Laboratory of Cancer Pharmacology
H指数:14
被引数:871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模态泛肿瘤细胞游离DNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

2026-02-260
OAAI
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)

癌症对肿瘤治疗场 (TTFields) 反应的转录组指纹

2025-07-100
OAAI
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics (vol 16, 229, 2025)

早期I期高级别浆液性卵巢癌中的免疫逃逸机制:对调节性T细胞动力学的见解(卷16,229,2025)

2025-05-160
OA
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB

恶性胸膜瘤相关的炎症微环境通过GPNMB促进肿瘤进展

2025-04-181
OA
Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: the MITO-16A/MANGO-OV2A clinical trial experience
2024-03-040
PRE
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer
2023-12-062
OA
Pan cancer transcriptomic response to tumor treating fields (TTFields)
2023-04-040
PRE
Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy
2022-10-0110
OAAI
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas (vol 25, pg 7565, 2019)
2020-03-021
OAAI